StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Gyre Therapeutics's price to book ratio was 4.2× on Nov 11, 2026, against 6.9× a year earlier. Over the last 5 years it ranged from 3.0× to 277.4×, with a median of 10.5×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.2×−2.1
2025Dec 31, 20256.3×−10.1
2024Dec 31, 202416.4×−261.0
2023Dec 29, 2023277.4×+268.9
2022Dec 30, 20228.5×+3.6
2021Dec 31, 20215.0×−17.3
2020Dec 31, 202022.2×+7.1
2019Dec 31, 201915.1×+4.2
2018Dec 31, 201810.9×−24.6
2017Dec 29, 201735.4×+29.5
2016Dec 30, 20165.9×−8.9
2015Dec 31, 201514.8×+13.9
2014Dec 31, 20140.9×−0.2
2013Dec 31, 20131.1×+0.2
2012Dec 31, 20120.9×−0.3
2011Dec 30, 20111.2×−10.1
2010Dec 31, 201011.2×–

More Gyre Therapeutics figures

See a number that looks wrong?